Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002820 · ClinicalTrials.gov registry record · Phase 2
A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601
A Phase 2 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01002820 is a Phase 2 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT01002820, a Phase 2 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.
Interventions
- DRUG ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002820
The ClinicalTrials.gov registry entry for NCT01002820 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ganaxolone is the first listed.
NCT01002820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002820 about?
NCT01002820 is a clinical study titled "A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601". This study is designed to provide ganaxolone to those patients deriving significant benefit from current treatment in protocol 1042-0601.
What is the current status of trial NCT01002820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2009-10. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01002820?
The interventions under investigation include: ganaxolone (DRUG).
Who is sponsoring clinical trial NCT01002820?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.